Oncology | pharmaphorum

News

Former Seagen CEO Siegall pops up at new biotech

Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.

News

Astellas GLOWing as Claudin drug aces gastric cancer trial

Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.

News

Could Daiichi Sankyo have another ADC winner in cancer?

New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.

News

Merck suffers a setback in its TIGIT programme

Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.

News

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

Could Daiichi Sankyo have another ADC winner in cancer?

New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.

News

Merck suffers a setback in its TIGIT programme

Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.

News

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

Former Seagen CEO Siegall pops up at new biotech

Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.

News

Astellas GLOWing as Claudin drug aces gastric cancer trial

Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.

Views & Analysis

R&D

Allogeneic therapies: The future of cancer treatment?

Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.

Oncology

World Thrombosis Day at 10, talking blood clots and cancer

A new 'Move Against Thrombosis' campaign and discussion of cancer-related blood clotting.

Deep Dive

Views & Analysis

ASCO highlights: the next generation of cancer therapy

For the last two years, the American Society of Clinical Oncology (ASCO) conference has been a reminder that even when COVID dominates headlines, amazing advances are still being made in ca

Oncology

Immunotherapy: building the fourth pillar of cancer treatmen...

Cancer treatment has been traditionally characterised by surgery, chemotherapy, and radiation.

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Oncology

Sponsored

Unlocking health data to improve oncology outcomes

The NHS’ globally unique health data ecosystem has the potential to improve health outcomes.

Podcasts

Oncology

Cancer control in a time of crisis - the pharmaphorum podcas...

During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with

Oncology

Understanding the tumour micro-environment – the pharmaphoru...

As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissu

Oncology

AI-derived cancer vaccines: the pharmaphorum podcast

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science off

Video

Oncology

JP Morgan 2023 – Adi Hoess

pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about

Oncology

Health Innovators – Dr. Jack Hoppin and Dr. John Babich

A few weeks ago, pharmaphorum Editor-in-Chief Jonah Comstock popped in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich at their WeWork coworking

Views & Analysis

Helsinn’s Riccardo Braglia on the patient perspective in can...

Swiss cancer care company Helsinn has become unique in the industry by remaining a family business over three generations.

White Papers

Sponsored

How pharma can help the post-COVID recovery of European canc...

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians i

Oncology

Sponsored

Preparing for the next decade of innovation in immuno-oncolo...

Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.

Debates & Insight

Sponsored

From promise to practice: immuno-oncology in action – the ne...

Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Meeting MSL training needs in an evolving landscape

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.

Oncology

Sponsored

Cost & Management of Oncology Combination Regimens

Overview

Partner Content

Oncology

Partner Content

Social Health and Cancer as a Chronic Condition

Data demonstrates the critical role of social health for people living with and beyond cancer

Oncology

Partner Content

CAR:T - Has biology outpaced the ability to deliver?

CAR-T, the latest development in research is catapulting cell therapy to the headlines.

Events

Partner Content

Former Seagen CEO Siegall pops up at new biotech

Astellas GLOWing as Claudin drug aces gastric cancer trial

Could Daiichi Sankyo have another ADC winner in cancer?

Merck suffers a setback in its TIGIT programme

Servier’s $1.8bn Agios deal delivers glioma prospect

Could Daiichi Sankyo have another ADC winner in cancer?

Merck suffers a setback in its TIGIT programme

Servier’s $1.8bn Agios deal delivers glioma prospect

Former Seagen CEO Siegall pops up at new biotech

Astellas GLOWing as Claudin drug aces gastric cancer trial

Allogeneic therapies: The future of cancer treatment?

World Thrombosis Day at 10, talking blood clots and cancer

ASCO highlights: the next generation of cancer therapy

Immunotherapy: building the fourth pillar of cancer treatmen...

How can digital and AI optimise the delivery of patient supp...

Clinical decision-making insights for haem/oncs

Unlocking health data to improve oncology outcomes

Cancer control in a time of crisis - the pharmaphorum podcas...

Understanding the tumour micro-environment – the pharmaphoru...

AI-derived cancer vaccines: the pharmaphorum podcast

JP Morgan 2023 – Adi Hoess

Health Innovators – Dr. Jack Hoppin and Dr. John Babich

Helsinn’s Riccardo Braglia on the patient perspective in can...

How pharma can help the post-COVID recovery of European canc...

Preparing for the next decade of innovation in immuno-oncolo...

From promise to practice: immuno-oncology in action – the ne...

How can digital and AI optimise the delivery of patient supp...

Meeting MSL training needs in an evolving landscape

Cost & Management of Oncology Combination Regimens

Social Health and Cancer as a Chronic Condition

CAR:T - Has biology outpaced the ability to deliver?

PM Society Digital Awards 2021

Former Seagen CEO Siegall pops up at new biotech

An inside guide to unlocking clinical research in the UK

Others Old
-About pharmaphorum
-Articles
--eyeforpharma Barcelona 2015
-Audio
-barelonalive 2016
-Cancer
-Diabetes
--Diabetes
-Disease Spotlight
--DMD Main
--LHON Main
-ESMO2016
-ESMO2016-related
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-Featured content right column
-Featured Event
-Jobs
--pharmaphorum-live
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
-Podcast
-Premium media
-Quintiles
--Quintiles-oncol-PC
--Quintiles - ContentIO
--Quintiles - Articles
--Quintiles - Oncol articles
-Roundtables
--AZ-roundtable-biographies-2017
--AZ-roundtable-interviews-2017
--AZ-roundtable-debate-2017
-Sales and Marketing
--News
--Insights
--Appointments
--Debates
--Debates & Insight
--Views & Analysis
--Partner Content
-Slider in events
-Slider in home page
-Slider in video
-Slider in views and analysis
-Slider in webinars
-Slider in whitepapers
-Spotlight
--Understanding HCPs
--Future of Generics
--Frontiers Health 2022
--Frontiers Health 2021
--Behavioural Science
--ASCO 2019 Live coverage
--AI in Pharma Marketing
--ASCO 2019 and the future of oncology
-Startups
--Views & Analysis
--News
-System
-Top pharmaceutical companies
--Bristol-Myers Squibb
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--Merck Inc
--GlaxoSmithKline
--Gilead
--AstraZeneca
--AbbVie
-Top pharmaceutical companies
--Merck Inc
-Top stories
-Transversal Categories
--Brexit
--Clinical
--Digital and Social Media
--US
---Articles
--UK & Europe
--Sales and Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
--Healthcare
-Veeva
-Veeva channel content articles
-Veeva channel content webinars
-Video
-Views and analysis
-Webinars in home page
-Whitepapers
Others
-Transversal Categories
--Clinical
--Sustainability
--Brexit
--Digital and Social Media
--Healthcare
--US
--UK & Europe
--Sales & Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
-Top stories
-About pharmaphorum
-Top pharmaceutical companies
--Gilead
--Merck Inc
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--GlaxoSmithKline
--Bristol-Myers Squibb
--AstraZeneca
--AbbVie
-test webinar
-System
-Startups
--News
--Views & Analysis
-Veeva channel content webinars
-Webinars in home page
--Live webinar
--Webinars On demand
-Veeva channel content articles
-Veeva
-Spotlight
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-ESMO2016-related
-ESMO2016
-Featured Event
-Disease Spotlight
--LHON Main
--DMD Main
-Diabetes
--Diabetes
-Cancer
-barelonalive 2016
-Audio
-Articles
--eyeforpharma Barcelona 2015
-Slider in whitepapers
-Featured content right column
-Jobs
--pharmaphorum-live
-Roundtables
--AZ-roundtable-interviews-2017
--AZ-roundtable-biographies-2017
--AZ-roundtable-debate-2017
-Slider in webinars
-Slider in views and analysis
-Slider in video
-Slider in home page
-Slider in events
-Quintiles
--Quintiles-oncol-PC
--Quintiles - Oncol articles
--Quintiles - ContentIO
--Quintiles - Articles
-Premium media
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
Home
-News
-Views & Analysis
-Deep Dive
-Webinars
--Live webinar
-Podcasts
-Videos
-White Papers
-Events
--JP Morgan
--LSX Investech
--Anthropy
--Reuters Pharma 2022
--World Cancer Series
--Hlth 2022
--PM Society Awards
--Patient Summit PC
--Frontiers Health 2022
--FHlive17
--ASCO 2018
-Digital Debates
-Podcasts & Videos
-Partner Content
--Events
--News
--Appointments
--Press releases
Digital
-Appointments
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Market Access
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Oncology
-Appointments
-Debates
-Insights
-News
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Patients
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
R&D
-Appointments
-Debates
-Debates & Insights
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Partner Content
-Debates & Insight
Sales & Marketing
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Spotlight on
-AI in Pharma Marketing
-ASCO 2019 and the future of oncology
-ASCO 2019 Live coverage
-Behavioural Science
-Frontiers Health 2021
-Frontiers Health 2022
-Future of Generics
-Understanding HCPs
-The Future of Generics

News

Views & Analysis

Deep Dive

Editor's Picks

Webinars

Podcasts

Video

White Papers

Debates & Insight

Partner Content

Editor's Picks